Elucidating the Role of Chest Wall Irradiation in 'Intermediate-risk' Breast Cancer: the MRC/EORTC SUPREMO Trial

Clinical Oncology

Volumn 20, Issue 1, 2008, Pages 31-34

  Kunkler, I H ^a   Canney, P ^b   van Tienhoven, G ^c   Russell, N S ^d  

^a UNIVERSITY OF EDINBURGH   (United Kingdom)

^b BEATSON WEST OF SCOTLAND CANCER CENTRE   (United Kingdom)

^c ACADEMIC MEDICAL CENTER   (Netherlands)

^d NETHERLANDS CANCER INSTITUTE   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRACYCLINE DERIVATIVE; ANTINEOPLASTIC AGENT; BRAIN NATRIURETIC PEPTIDE; CYCLOPHOSPHAMIDE; EPIRUBICIN; FLUOROURACIL; METHOTREXATE; TRASTUZUMAB;

AXILLARY LYMPH NODE; BREAST CANCER; BREAST RECONSTRUCTION; CANCER MORTALITY; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER RISK; CANCER SURVIVAL; CARDIOTOXICITY; CHEST WALL IRRADIATION; CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; EDITORIAL; HEART LEFT VENTRICLE FAILURE; HUMAN; ISCHEMIC HEART DISEASE; LYMPH NODE IRRADIATION; LYMPH NODE METASTASIS; LYMPHADENECTOMY; MAMMOGRAPHY; MASTECTOMY; POSTOPERATIVE CARE; PRIORITY JOURNAL; PROGNOSIS; QUALITY OF LIFE;

BREAST NEOPLASMS; COMBINED MODALITY THERAPY; FEMALE; HEART; HUMANS; LYMPHATIC METASTASIS; MASTECTOMY; NEOPLASM RECURRENCE, LOCAL; RADIATION DOSAGE; RADIOTHERAPY, ADJUVANT; RISK FACTORS; THORACIC WALL;

EID: 38149108279     PISSN: 09366555     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.clon.2007.10.004     Document Type: Editorial

References (21)

1. Overgaard M., Hansen P.S., Overgaard J., et al. Postoperative radiotherapy in high-risk premenopausal women with breast cancer who receive adjuvant chemotherapy. Danish Breast Cancer Cooperative Group 82b Trial. N Engl J Med 337 14 (1997) 949-955
2. Ragaz J., Jackson S.M., Le N., et al. Adjuvant radiotherapy and chemotherapy in node-positive premenopausal women with breast cancer. N Engl J Med 337 (1997) 956-962
3. Overgaard M., Jensen M.B., Overgaard J., et al. Postoperative radiotherapy in high-risk postmenopausal breast-cancer patients given adjuvant tamoxifen: Danish Breast Cancer Cooperative Group DBCCG 82c randomised trial. Lancet 353 (1999) 1641-1648
4. Whelan T.J., Julian J., Wright J., Jadad A.R., and Levine M.L. Does loco-regional radiation therapy improve survival in breast cancer? A meta-analysis. J Clin Oncol 18 (2000) 1220-1229
5. Clarke M., Collins R., Darby S., et al., Early Breast Cancer Trialists' Collaborative Group (EBCTCG). Effects of radiotherapy and of differences in the extent of surgery for early breast cancer on local recurrence and 15-year survival: an overview of the randomised trials. Lancet 366 (2005) 2087-2106
6. Recht A., Bartelink H., Fourquet A., et al. Postmastectomy radiotherapy: questions for the twenty-first century. J Clin Oncol 16 (1998) 2886-2889
7. Ragaz J., Olivotto I.A., Spinelli J.J., et al. Locoregional radiation therapy in patients with high-risk breast cancer receiving adjuvant chemotherapy: 20-year results of the British Columbia randomized trial. J Natl Cancer Inst 97 (2005) 116-126
8. Danish Breast Cancer Cooperative Group, Nielsen H.M., Overgaard M., Grau C., Jensen A.R., and Overgaard J. Study of failure pattern among high-risk breast cancer patients with or without postmastectomy radiotherapy in addition to adjuvant systemic therapy: long-term results from the Danish Breast Cancer Cooperative Group DBCCG 82 b and c randomized studies. J Clin Oncol 24 (2006) 2268-2275
9. Nielsen H.M., Overgaard M., Grau C., Jensen A.R., and Overgaard J. Loco-regional recurrence after mastectomy in high-risk breast cancer risk and prognosis. An analysis of patients from the DBCCG 82 b&c randomization trials. Radiother Oncol 79 (2006) 147-155
10. EBCTCG. Highlights from the early breast cancer triallists' collaborative group (EBCTCG) 2005-2006 worldwide overview. 29th San Antonio Breast Cancer Symposium 2006. Breast Cancer Res Treat 100 Suppl 1 (2006) S19 [abstract 40]
11. Poortmans P.M., Venselaar J.L., Struikmans H., et al. The potential impact of treatment variations on the results of radiotherapy of the internal mammary lymph node chain: a quality-assurance report on the dummy run of EORTC phase III randomized trial 22922/10925 in stage I-III breast cancer(1). Int J Radiat Oncol Biol Phys 49 (2001) 1399-1408
12. Rutqvist L.E., Lax I., Fornander T., and Johansson H. Cardiovascular mortality in a randomised trial of adjuvant radiation therapy versus surgery alone in primary breast cancer. Int J Radiat Oncol Biol Phys 22 (1992) 887-896
13. Hojris I., Andersen J., Overgaard M., and Overgaard J. Late treatment-related morbidity in breast cancer patients randomized to postmastectomy radiotherapy and systemic treatment versus systemic treatment alone. Acta Oncol 39 3 (2000) 355-372
14. Van de Steene J., Vinh-Hung V., Cutuli B., and Storme G. Adjuvant radiotherapy for breast cancer: effects of longer follow-up. Radiother Oncol 72 (2004) 35-43
15. Overgaard M., Nielsen H.M., and Overgaard J. Is the benefit of postmastectomy irradiation limited to patients with four or more positive nodes, as recommended in international consensus? A subgroup analysis of the DBCCG 82 b&c randomized trials. Radiother Oncol 82 (2007) 247-253
16. Poortmans P. A bright future for radiotherapy in breast cancer. Radiother Oncol 82 (2007) 243-246
17. Kunkler I., van Tienhoven G., Dixon M., et al. Postmastectomy radiotherapy should not be the standard for care patients with 1-3 positive nodes. Radiother Oncol 84 (2007) 103-104
18. Poole C.J., Earl H.M., Hiller L., et al. Epirubicin and cyclophosphamide, methotrexate, and fluorouracil as adjuvant therapy for early breast cancer. N Engl J Med 355 (2006) 1851-1862
19. Levine M.N., Pritchard K.I., Bramwell V.H., et al., National Cancer Institute of Canada Clinical Trials Group. Randomized trial comparing cyclophosphamide, epirubicin, and fluorouracil with cyclophosphamide, methotrexate, and fluorouracil in premenopausal women with node-positive breast cancer: update of National Cancer Institute of Canada Clinical Trials Group Trial MA5. J Clin Oncol 23 (2005) 5166-5170
20. Kaija H., and Maunu P. Tangential breast irradiation with or without internal mammary chain irradiation: results of a randomized trial. Radiother Oncol 36 (1995) 172-176
21. Piccart-Gebhart M.J., Procter M., Leyland-Jones B., et al. Trastuzumab after adjuvant chemotherapy in HER-2 positive breast cancer. N Engl J Med 353 (2005) 1650-1672